

Correspondence

Monitoring of thyroid function in patients who exhibit IgE against thyroperoxidase while taking omalizumab?

To the Editor:

In a recent study entitled “Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase,”¹ the authors note that “[t]he number of patients with notable changes in laboratory values during the study was small.” No details of which laboratory studies were performed and whether they included monitoring of thyroid status are provided. This is surprising in view of the purported focus of the study on the safety of a medication in a population at risk for thyroid disease. Because there is at least 1 report in the literature of altered thyroid function temporally related to use of omalizumab in a patient with antithyroid antibodies and chronic urticaria that is not cited by the authors, some of the readers

might appreciate a clarification of whether these “notable changes” included measures of thyroid function and antibody levels.²

David H. Dreyfus, MD, PhD

From the Clinical Faculty, Yale School of Medicine, Center for Allergy, Asthma, and Immunology, Waterbury, Conn. E-mail: dhdreyfus@pol.net.

Disclosure of potential conflict of interest: The author declares that he has no relevant conflicts of interest.

REFERENCES

1. Maurer M, Altrichter S, Bieber T, Biedermann T, Bräutigam M, Seyfried S, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. *J Allergy Clin Immunol* 2011;128:202-9.
2. Dreyfus DH. Observations on the mechanism of omalizumab as a steroid-sparing agent in autoimmune or chronic idiopathic urticaria and angioedema. *Ann Allergy Asthma Immunol* 2008;100:624-5.

doi:10.1016/j.jaci.2011.10.040